Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant.
Department of Internal Medicine V.
Aleksandar
A
Radujkovic
Michael
M
Hundemer
Christoph
C
Eisenbach
Thomas
T
Luft
Roland
R
Penzel
Hartmut
H
Goldschmidt
Anthony D
AD
Ho
Frauke
F
Bellos
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000175:diagnosis* / Q000209:etiology*; D008264:Macrophages / Q000469:parasitology / Q000473:pathology; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects*; D009101:Multiple Myeloma / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D019653:Myeloablative Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D014182:Transplantation, Autologous
D019653:Myeloablative Agonists; D008558:Melphalan